JP2023542093A - 抗腫瘍治療におけるチアウラニブと免疫チェックポイント阻害剤との組み合わせの使用 - Google Patents

抗腫瘍治療におけるチアウラニブと免疫チェックポイント阻害剤との組み合わせの使用 Download PDF

Info

Publication number
JP2023542093A
JP2023542093A JP2023515686A JP2023515686A JP2023542093A JP 2023542093 A JP2023542093 A JP 2023542093A JP 2023515686 A JP2023515686 A JP 2023515686A JP 2023515686 A JP2023515686 A JP 2023515686A JP 2023542093 A JP2023542093 A JP 2023542093A
Authority
JP
Japan
Prior art keywords
cancer
tumor
inhibitor
combination
thiauranib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023515686A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542093A5 (https=
Inventor
ルー、シエンピン
パン、トースー
チョウ、イウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Chipscreen Biosciences Co Ltd
Original Assignee
Shenzhen Chipscreen Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Chipscreen Biosciences Co Ltd filed Critical Shenzhen Chipscreen Biosciences Co Ltd
Publication of JP2023542093A publication Critical patent/JP2023542093A/ja
Publication of JP2023542093A5 publication Critical patent/JP2023542093A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023515686A 2020-09-09 2021-09-03 抗腫瘍治療におけるチアウラニブと免疫チェックポイント阻害剤との組み合わせの使用 Pending JP2023542093A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010939961 2020-09-09
CN202010939961.4 2020-09-09
PCT/CN2021/116498 WO2022052874A1 (zh) 2020-09-09 2021-09-03 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用

Publications (2)

Publication Number Publication Date
JP2023542093A true JP2023542093A (ja) 2023-10-05
JP2023542093A5 JP2023542093A5 (https=) 2024-09-06

Family

ID=80632631

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515686A Pending JP2023542093A (ja) 2020-09-09 2021-09-03 抗腫瘍治療におけるチアウラニブと免疫チェックポイント阻害剤との組み合わせの使用

Country Status (7)

Country Link
US (1) US20230321074A1 (https=)
EP (1) EP4212160A4 (https=)
JP (1) JP2023542093A (https=)
KR (1) KR20230066401A (https=)
CN (2) CN114224889B (https=)
TW (1) TW202214243A (https=)
WO (1) WO2022052874A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117597124A (zh) * 2021-07-08 2024-02-23 深圳微芯生物科技股份有限公司 西奥罗尼及其联合用药治疗乳腺癌的用途
WO2023160647A1 (zh) * 2022-02-24 2023-08-31 康方药业有限公司 包含抗ctla4-抗pd-1双特异性抗体和西奥罗尼的药物组合
WO2023193705A1 (zh) * 2022-04-07 2023-10-12 深圳微芯生物科技股份有限公司 西奥罗尼在抗胰腺癌中的用途
CN115177620A (zh) * 2022-07-18 2022-10-14 厦门大学附属第一医院 西奥罗尼或其药学上可接受的盐在制备预防或治疗滤泡淋巴瘤的药物中的应用
CN119451679A (zh) * 2022-08-24 2025-02-14 应世生物科技(南京)有限公司 Fak抑制剂及微管抑制剂的药物组合及用途
WO2024055179A1 (zh) * 2022-09-14 2024-03-21 同济大学苏州研究院 Pd-1抗体药物继发耐药免疫抑制靶点及应用
CN115845052B (zh) * 2022-12-28 2023-12-29 广州誉衡生物科技有限公司 一种药物组合物和药物制剂及其在治疗结肠癌中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100298358A1 (en) * 2009-05-22 2010-11-25 Shenzhen Chipscreen Biosciences Ltd. Naphthamide Derivatives As Multi-Target Protein Kinase Inhibitors and Histone Deacetylase Inhibitors
WO2018223923A1 (zh) * 2017-06-05 2018-12-13 江苏恒瑞医药股份有限公司 Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途
WO2019096194A1 (zh) * 2017-11-16 2019-05-23 江苏恒瑞医药股份有限公司 Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
CN109893654A (zh) * 2017-12-11 2019-06-18 江苏恒瑞医药股份有限公司 Vegfr抑制剂治疗肿瘤的方法
JP2019529504A (ja) * 2016-09-27 2019-10-17 シンセン チップスクリーン バイオサイエンセズ カンパニー リミテッド 非溶媒和物結晶及びその製造方法、並びに応用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3079699A4 (en) 2013-12-11 2017-07-19 Glaxosmithkline LLC Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
PL3102605T3 (pl) 2014-02-04 2019-06-28 Pfizer Inc. Połączenie antagonisty pd-1 i inhibitora vegfr do leczenia nowotworu
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
TWI764943B (zh) 2016-10-10 2022-05-21 大陸商蘇州盛迪亞生物醫藥有限公司 一種抗pd-1抗體和vegfr抑制劑聯合在製備治療癌症的藥物中的用途
CN106963948A (zh) 2017-05-12 2017-07-21 顾艳宏 阿帕替尼与Anti‑PD‑1抗体联用在制备结肠癌药物中的应用
KR102831159B1 (ko) * 2018-04-16 2025-07-07 온퀄리티 파마슈티컬스 차이나 리미티드 암 치료의 부작용을 예방하거나 치료하기 위한 방법
CN114681455A (zh) * 2018-08-17 2022-07-01 深圳微芯生物科技股份有限公司 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途
CN109908143B (zh) * 2018-12-18 2021-11-19 厦门大学附属第一医院 西奥罗尼在制备治疗急性髓系白血病药物的新用途
CN112741905A (zh) * 2019-10-30 2021-05-04 江苏恒瑞医药股份有限公司 Vegfr抑制剂与抗pd-1抗体联合在制备治疗妊娠滋养细胞肿瘤的药物中的用途
WO2023160647A1 (zh) * 2022-02-24 2023-08-31 康方药业有限公司 包含抗ctla4-抗pd-1双特异性抗体和西奥罗尼的药物组合

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100298358A1 (en) * 2009-05-22 2010-11-25 Shenzhen Chipscreen Biosciences Ltd. Naphthamide Derivatives As Multi-Target Protein Kinase Inhibitors and Histone Deacetylase Inhibitors
JP2019529504A (ja) * 2016-09-27 2019-10-17 シンセン チップスクリーン バイオサイエンセズ カンパニー リミテッド 非溶媒和物結晶及びその製造方法、並びに応用
WO2018223923A1 (zh) * 2017-06-05 2018-12-13 江苏恒瑞医药股份有限公司 Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途
WO2019096194A1 (zh) * 2017-11-16 2019-05-23 江苏恒瑞医药股份有限公司 Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
CN109893654A (zh) * 2017-12-11 2019-06-18 江苏恒瑞医药股份有限公司 Vegfr抑制剂治疗肿瘤的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANTI-CANCER DRUGS, vol. 30, no. 9, JPN6025037169, 2019, pages 909 - 916, ISSN: 0005811271 *

Also Published As

Publication number Publication date
CN114224889B (zh) 2026-04-10
KR20230066401A (ko) 2023-05-15
US20230321074A1 (en) 2023-10-12
EP4212160A4 (en) 2024-10-09
EP4212160A1 (en) 2023-07-19
WO2022052874A1 (zh) 2022-03-17
CN114224889A (zh) 2022-03-25
CN121943909A (zh) 2026-05-01
TW202214243A (zh) 2022-04-16

Similar Documents

Publication Publication Date Title
JP2023542093A (ja) 抗腫瘍治療におけるチアウラニブと免疫チェックポイント阻害剤との組み合わせの使用
ES2904880T3 (es) Terapia combinada con inhibidores de Notch y de PD-1 o PD-L1
JP7092775B2 (ja) がんを治療するための薬物の調製における、抗ｐｄ‐１抗体とｖｅｇｆｒ阻害剤とを組み合わせた使用
CN111065411B (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
TWI685341B (zh) 阿帕替尼和c-Met抑制劑聯合在製備治療腫瘤的藥物中的用途
WO2014142220A1 (ja) 抗腫瘍剤
WO2019072220A1 (zh) Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
WO2023035223A1 (zh) 药物组合物及其用途
WO2020249018A1 (zh) 治疗驱动基因阳性肺癌的联用药物组合物
JP2025163103A (ja) 放射線および／または抗がん治療補助療法としてアデノシン二リン酸リボースの活用
CN113811298A (zh) 用于联合治疗小细胞肺癌的喹啉衍生物
CN120437288A (zh) 治疗卵巢癌的药物组合
JP7381115B2 (ja) 組成物及びがん治療用医薬品の調製におけるその応用
JP7357386B2 (ja) 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用
CN110831604A (zh) 用于肿瘤治疗或预防的药物组合物、方法及其用途
US20190183893A1 (en) Low dose of sildenafil as an antitumor drug
WO2021213523A1 (zh) 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途
JP7805005B2 (ja) 腫瘍治療の医薬組み合わせとその使用
US20230404998A1 (en) Combination Therapies for Treating Cancer
RU2827402C2 (ru) Фармацевтическая композиция, содержащая пиридинаминное соединение, и ее применение при ros1-положительном немелкоклеточном раке легкого
WO2023030437A1 (zh) 一种pi3k抑制剂与btk抑制剂在制备治疗淋巴瘤的药物中的用途
CN119454969A (zh) 含pd-l1小分子抑制剂的药物组合及其应用
US20120252829A1 (en) Tivozanib and capecitabine combination therapy
NZ788180A (en) Combination therapy with notch and pd-1 or pd-l1 inhibitors
HK1255299A1 (en) Use of combination of anti-pd-1 antibody and vegfr inhibitor in preparation of drug for treating cancers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260306